...and to start a Phase II trial in 1H15. Synthetic Biologics acquired the product from Prev AbR LLC...

...based on Synthetic close of $1.92 prior to the deal close (see BioCentury, Nov. 19). Prev AbR LLC...

...an IND for SYN-004 based on the compounds' structural similarities. P1A completed Phase II testing. Prev AbR LLC...